Richard Straube, MD, has been appointed senior vice president and chief medical officer at Soligenix, Inc. Dr. Straube will lead the company's clinical research with responsibility for the execution of its multiple clinical programs, including its Phase II study in oral mucositis and its Phase II/III study in pediatric Crohn's disease. Dr. Straube has more than 35 years of experience in both academia and industry, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides. He is a board-certified pediatrician with clinical research expertise in host-response modulation.
At Centocor, Dr. Straube managed programs that included assessments of immunomodulation using monoclonal removal of inciting molecular triggers, removal of internal immune-messengers, augmentation of normal host defenses, and maintenance of normal sub-cellular function in the face of injury. He was also the founding chief medical officer for INO Therapeutics and was responsible for the clinical trials and subsequent approval of inhaled nitric oxide for the treatment of persistent pulmonary hypertension in newborns.
"We are delighted to welcome Rick to our team, as he will leverage his extensive drug development expertise in leading our oral mucositis and pediatric Crohn's disease clinical studies," said Christopher J. Schaber, Ph.D., president and chief executive officer of Soligenix. "His clinical experience with trial design, conduct and analysis, as well as his background in immunomodulation and pediatrics will be advantageous to us as we advance our programs."